Limits...
GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor.

Takagi K, Moriguchi T, Miki Y, Nakamura Y, Watanabe M, Ishida T, Yamamoto M, Sasano H, Suzuki T - Cancer Sci. (2014)

Bottom Line: GATA4 status was significantly associated with nuclear grade and van Nuys classification in DCIS and was positively associated with distant metastasis, histological grade and HER2 status, but negatively correlated with progesterone receptor labeling index in IDC.Subsequent multivariate analysis demonstrated that GATA4 status was an independent prognostic factor for both disease-free and breast cancer-specific survival of IDC patients.All of these results indicate that GATA4 plays important roles in the progression of breast carcinoma from an early stage and that immunohistochemical GATA4 status is considered a potent prognostic factor in human breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH

Related in: MedlinePlus

Disease-free (a) and breast cancer-specific survival (b–e) of stage I–III patients according to GATA4 status. The solid line shows GATA4-positive cases and the dashed line shows GATA4-negative cases. (a, b) Total cases (n = 140); (c) cases negative for lymph node metastasis (n = 89); (d) estrogen receptor (ER)-positive cases that received adjuvant endocrine therapy following surgery (n = 81); and (e) cases that received adjuvant chemotherapy after surgery (n = 95). Statistical analysis was performed using the log-rank test. P-values < 0.05 were considered significant and are shown in bold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317835&req=5

fig03: Disease-free (a) and breast cancer-specific survival (b–e) of stage I–III patients according to GATA4 status. The solid line shows GATA4-positive cases and the dashed line shows GATA4-negative cases. (a, b) Total cases (n = 140); (c) cases negative for lymph node metastasis (n = 89); (d) estrogen receptor (ER)-positive cases that received adjuvant endocrine therapy following surgery (n = 81); and (e) cases that received adjuvant chemotherapy after surgery (n = 95). Statistical analysis was performed using the log-rank test. P-values < 0.05 were considered significant and are shown in bold.

Mentions: As demonstrated in Figure3(a), GATA4 status was significantly associated with an increased incidence of recurrence in stage I–III patients (n = 140) (P = 0.0069 using the log-rank test). Association between GATA4 status and breast cancer-specific survival is summarized in Figure3(b) and a significant association was detected between GATA4 status and an adverse clinical outcome of patients (P = 0.0013 using the log-rank test). Interestingly, this association was also significant (P = 0.0032) in stage IV patients (n = 23) (data not shown). A tendency between GATA4 status and a worse prognosis was observed regardless of lymph node status in stage I–III cases (lymph node-negative group: P = 0.19 for disease-free survival [data not shown] and P = 0.0053 for breast cancer-specific survival [Fig.3c]; lymph node-positive group: P = 0.017 for disease-free survival [data not shown] and P = 0.067 for breast cancer-specific survival [data not shown]). Associations between GATA4 status and the clinical outcome of patients according to ER and HER2 status are shown in Figures S1 and S2, respectively.


GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor.

Takagi K, Moriguchi T, Miki Y, Nakamura Y, Watanabe M, Ishida T, Yamamoto M, Sasano H, Suzuki T - Cancer Sci. (2014)

Disease-free (a) and breast cancer-specific survival (b–e) of stage I–III patients according to GATA4 status. The solid line shows GATA4-positive cases and the dashed line shows GATA4-negative cases. (a, b) Total cases (n = 140); (c) cases negative for lymph node metastasis (n = 89); (d) estrogen receptor (ER)-positive cases that received adjuvant endocrine therapy following surgery (n = 81); and (e) cases that received adjuvant chemotherapy after surgery (n = 95). Statistical analysis was performed using the log-rank test. P-values < 0.05 were considered significant and are shown in bold.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317835&req=5

fig03: Disease-free (a) and breast cancer-specific survival (b–e) of stage I–III patients according to GATA4 status. The solid line shows GATA4-positive cases and the dashed line shows GATA4-negative cases. (a, b) Total cases (n = 140); (c) cases negative for lymph node metastasis (n = 89); (d) estrogen receptor (ER)-positive cases that received adjuvant endocrine therapy following surgery (n = 81); and (e) cases that received adjuvant chemotherapy after surgery (n = 95). Statistical analysis was performed using the log-rank test. P-values < 0.05 were considered significant and are shown in bold.
Mentions: As demonstrated in Figure3(a), GATA4 status was significantly associated with an increased incidence of recurrence in stage I–III patients (n = 140) (P = 0.0069 using the log-rank test). Association between GATA4 status and breast cancer-specific survival is summarized in Figure3(b) and a significant association was detected between GATA4 status and an adverse clinical outcome of patients (P = 0.0013 using the log-rank test). Interestingly, this association was also significant (P = 0.0032) in stage IV patients (n = 23) (data not shown). A tendency between GATA4 status and a worse prognosis was observed regardless of lymph node status in stage I–III cases (lymph node-negative group: P = 0.19 for disease-free survival [data not shown] and P = 0.0053 for breast cancer-specific survival [Fig.3c]; lymph node-positive group: P = 0.017 for disease-free survival [data not shown] and P = 0.067 for breast cancer-specific survival [data not shown]). Associations between GATA4 status and the clinical outcome of patients according to ER and HER2 status are shown in Figures S1 and S2, respectively.

Bottom Line: GATA4 status was significantly associated with nuclear grade and van Nuys classification in DCIS and was positively associated with distant metastasis, histological grade and HER2 status, but negatively correlated with progesterone receptor labeling index in IDC.Subsequent multivariate analysis demonstrated that GATA4 status was an independent prognostic factor for both disease-free and breast cancer-specific survival of IDC patients.All of these results indicate that GATA4 plays important roles in the progression of breast carcinoma from an early stage and that immunohistochemical GATA4 status is considered a potent prognostic factor in human breast cancer patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Show MeSH
Related in: MedlinePlus